Aurinia Pharmaceuticals INC 8-K filings

Aurinia Pharmaceuticals announced robust financial results for the second quarter of 2026, showcasing significant year-over-year growth in revenue and net income, primarily driven by strong net product sales of LUPKYNIS.

Aurinia Pharmaceuticals shareholders re-elected the board of directors and approved executive compensation at the 2026 annual meeting.

Aurinia Pharmaceuticals Inc. has successfully completed its acquisition of Kezar Life Sciences, Inc. through a tender offer and subsequent merger, with the transaction closing on May 11, 2026.

Aurinia Pharmaceuticals reported strong Q1 2026 financial results, with total revenue up 24% year-over-year, driven by significant growth in LUPKYNIS net product sales.

Aurinia Pharmaceuticals announced a definitive agreement to acquire Kezar Life Sciences for $6.955 in cash per share plus a contingent value right.

Aurinia Pharmaceuticals announced a significant leadership transition, appointing Kevin Tang as Chief Executive Officer and making other key executive changes.

Aurinia Pharmaceuticals announced robust financial results for Q4 and full-year 2025, driven by significant LUPKYNIS sales growth, and provided optimistic 2026 revenue guidance.

Aurinia Pharmaceuticals Inc. announced robust third-quarter 2025 financial results, driven by strong LUPKYNIS sales, and raised its full-year 2025 revenue and product sales guidance.

Aurinia Pharmaceuticals announced robust financial results for the second quarter of 2025, with significant revenue and net income growth, and approved an additional $150 million for its share repurchase program.

Aurinia Pharmaceuticals Inc. announced positive Phase 1 single-ascending-dose study results for its dual BAFF/APRIL inhibitor, aritinercept (AUR200), demonstrating robust immunoglobulin reductions and good tolerability, supporting once-monthly dosing for autoimmune diseases.

Aurinia Pharmaceuticals' shareholders approved an amended equity incentive plan and bylaw changes at the annual general meeting held on May 15, 2025.

Aurinia Pharmaceuticals announces a 24% increase in total revenue for Q1 2025, driven by strong LUPKYNIS sales.

Aurinia Pharmaceuticals announces a 34% increase in total revenue for 2024, driven by strong LUPKYNIS sales, and provides optimistic revenue guidance for 2025.

Aurinia Pharmaceuticals reported a strong third quarter with significant revenue growth and announced a strategic restructuring to focus on LUPKYNIS and AUR200 development, including a 45% workforce reduction.

Aurinia Pharmaceuticals has restructured its board of directors, accepting the resignations of three directors who received less than majority support at the annual meeting, while retaining the CEO as a director and appointing a new director.

Aurinia Pharmaceuticals announced a successful second quarter of 2024, marked by significant revenue growth, positive free cash flow, and advancements in their pipeline.

Aurinia Pharmaceuticals' annual general meeting saw the re-election of all director nominees, but four directors received less than majority support, and shareholders rejected the executive compensation plan and an amendment to the equity incentive plan.

Aurinia Pharmaceuticals achieved significant revenue growth in the first quarter of 2024 and expects to be cash flow positive in the second quarter, ahead of previous projections.

Aurinia Pharmaceuticals will terminate the employment of Dr. Volker Knappertz, Executive Vice President of Research and Development, as part of a previously announced restructuring.

Aurinia Pharmaceuticals will discontinue development of two research programs, implement a share repurchase program of up to $150 million, and focus on commercializing its drug LUPKYNIS.